Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 1/20 | 0.44 |
| ▸ | CTSK | P43235 | 8/20 | 0.38 |
| ▸ | CTSS | P25774 | 4/20 | 0.38 |
| ▸ | PLA2G2C | Q5R387 | 2/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA7 | P43166 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25320182 | 1.00 | APLNR (0.44) | APLNRCTSKCTSSPLA2G2CATM | |
| SCHEMBL5691699 | 0.87 | CA1 (0.46) | CTSKCTSSPLA2G2CATMCA1 | |
| SCHEMBL31030113 | 0.84 | APLNR (0.48) | APLNRCTSKCTSSATMCA1 | |
| SCHEMBL28467147 | 0.84 | CA1 (0.40) | CTSKCTSSPLA2G2CATMCA1 | |
| SCHEMBL28467148 | 0.84 | CA1 (0.40) | CTSKCTSSPLA2G2CATMCA1 | |
| SCHEMBL25323353 | 0.83 | APLNR (0.44) | APLNRCTSKCTSSCA1CA2 | |
| SCHEMBL25323351 | 0.83 | APLNR (0.44) | APLNRCTSKCTSSCA1CA2 | |
| SCHEMBL31030138 | 0.83 | APLNR (0.47) | APLNRCTSKCTSSATMCA1 | |
| SCHEMBL19337973 | 0.82 | CTSK (0.40) | CTSKCTSSPLA2G2CATMCA1 | |
| SCHEMBL25319084 | 0.81 | CA1 (0.41) | CTSKCTSSPLA2G2CATMCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12459922-B2 | PARP7 inhibitors | GILEAD SCIENCES, INC. (US) | 2025-11-04 | — | — | US | disclosed |
| EP-4469448-A1 | PARP7 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2024-12-04 | — | — | EP | disclosed |
| CN-118591537-A | PARP7 inhibitors | 吉利德科学公司 | 2024-09-03 | — | — | CN | disclosed |
| US-20230365529-A1 | PARP7 INHIBITORS | GILEAD SCIENCES, INC. | 2023-11-16 | — | — | US | disclosed |
| US-20230365529-A1 | PARP7 INHIBITORS | GILEAD SCIENCES, INC. | 2023-11-16 | — | — | US | disclosed |
| WO-2023147418-A1 | PARP7 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023147418-A1 | PARP7 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12459922-B2 | PARP7 inhibitors | PARP1, PARP11, PARP2 | APLNR 3634/4885CTSK 2511/4885CTSS 3101/4885 |
| US-20230365529-A1 | PARP7 INHIBITORS | PARP1, PARP11, PARP2 | APLNR 3634/4885CTSK 2511/4885CTSS 3101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.